Genetic Alterations Associated with Sporadic Congenital Hydrocephalus
|
By LabMedica International staff writers Posted on 02 Nov 2020 |

Image: A neural stem cell model of sporadic congenital hydrocephalus (Photo courtesy of Yale University School of Medicine).
Congenital hydrocephalus (CH), characterized by enlarged brain ventricles, is considered a disease of excessive cerebrospinal fluid (CSF) accumulation and thereby treated with neurosurgical CSF diversion with high morbidity and failure rates.
Congenital hydrocephalus is present in the infant prior to birth, meaning the fetus developed hydrocephalus in utero during fetal development. The most common cause of congenital hydrocephalus is aqueductal stenosis, which occurs when the narrow passage between the third and fourth ventricles in the brain is blocked or too narrow to allow sufficient CSF to drain.
A multidisciplinary team at Yale University School of Medicine (New Haven, CT, USA) performed whole-exome sequencing of 381 individuals with sporadic congenital hydrocephalus who were treated with neurosurgery, a cohort that included 232 parent-offspring trios. Another 1,798 trios of unaffected siblings and parents of individuals with autism spectrum disorder were analyzed in parallel as a control group.
The team uncovered 12 genes with two or more de novo mutations each that were predicted to be protein damaging. Five of these genes: TRIM71, SMARCC1, PTEN, PIK3CA, and FOXJ1, had significantly more mutations than expected. The investigators further estimated that about 22% of sporadic congenital hydrocephalus are due to rare, damaging mutations. The teams’ analysis additionally implicated a number of genes in the PI3K signaling pathway in congenital hydrocephalus. These genes regulate cell growth, proliferation, and differentiation in numerous tissues, including developing neural stem cells. In particular, they uncovered three de novo mutations in PI3KCA, three in PTEN, and two in MTOR.
Individuals with mutations in TRIM71, which maintains stem cell pluripotency, are more likely to have cranial nerve defect, non-obstructive inter-hemispheric cysts, and hearing loss. Meanwhile, individuals with mutations in SMARCC1, which regulates gene expression needed for neural stem cell proliferation, differentiation, and survival during telencephalon development, are more likely to have aqueductal stenosis and cardiac and skeletal abnormalities.
All together, the known, high-confidence, and probable risk genes for congenital hydrocephalus converge in gene co-expression networks of the mid-gestational human cortex, In particular, the congenital hydrocephalus risk genes converge on a network previously linked to autism spectrum disorder that is enriched for neuronal differentiation and RNA processing gene ontology terms.
Kristopher T. Kahle, MD, PhD, an assistant professor of neurosurgery and a senior author of the study, said, “It is possible that some of the neurological problems that many of these congenital hydrocephalus patients have may not be due to inadequately working shunts, but are in fact neurodevelopmental sequelae of a genetic condition that alters neuronal function.”
The authors concluded that that genetic disruptions affecting early brain development may drive sporadic congenital hydrocephalus. Their data implicate genetically encoded neural stem cell dysregulation and an associated impairment of fetal neurogliogenesis as primary pathophysiological events in a significant number of congenital hydrocephalus cases. The study was published on October 19, 2020 in the journal Nature Medicine.
Related Links:
Yale University School of Medicine
Congenital hydrocephalus is present in the infant prior to birth, meaning the fetus developed hydrocephalus in utero during fetal development. The most common cause of congenital hydrocephalus is aqueductal stenosis, which occurs when the narrow passage between the third and fourth ventricles in the brain is blocked or too narrow to allow sufficient CSF to drain.
A multidisciplinary team at Yale University School of Medicine (New Haven, CT, USA) performed whole-exome sequencing of 381 individuals with sporadic congenital hydrocephalus who were treated with neurosurgery, a cohort that included 232 parent-offspring trios. Another 1,798 trios of unaffected siblings and parents of individuals with autism spectrum disorder were analyzed in parallel as a control group.
The team uncovered 12 genes with two or more de novo mutations each that were predicted to be protein damaging. Five of these genes: TRIM71, SMARCC1, PTEN, PIK3CA, and FOXJ1, had significantly more mutations than expected. The investigators further estimated that about 22% of sporadic congenital hydrocephalus are due to rare, damaging mutations. The teams’ analysis additionally implicated a number of genes in the PI3K signaling pathway in congenital hydrocephalus. These genes regulate cell growth, proliferation, and differentiation in numerous tissues, including developing neural stem cells. In particular, they uncovered three de novo mutations in PI3KCA, three in PTEN, and two in MTOR.
Individuals with mutations in TRIM71, which maintains stem cell pluripotency, are more likely to have cranial nerve defect, non-obstructive inter-hemispheric cysts, and hearing loss. Meanwhile, individuals with mutations in SMARCC1, which regulates gene expression needed for neural stem cell proliferation, differentiation, and survival during telencephalon development, are more likely to have aqueductal stenosis and cardiac and skeletal abnormalities.
All together, the known, high-confidence, and probable risk genes for congenital hydrocephalus converge in gene co-expression networks of the mid-gestational human cortex, In particular, the congenital hydrocephalus risk genes converge on a network previously linked to autism spectrum disorder that is enriched for neuronal differentiation and RNA processing gene ontology terms.
Kristopher T. Kahle, MD, PhD, an assistant professor of neurosurgery and a senior author of the study, said, “It is possible that some of the neurological problems that many of these congenital hydrocephalus patients have may not be due to inadequately working shunts, but are in fact neurodevelopmental sequelae of a genetic condition that alters neuronal function.”
The authors concluded that that genetic disruptions affecting early brain development may drive sporadic congenital hydrocephalus. Their data implicate genetically encoded neural stem cell dysregulation and an associated impairment of fetal neurogliogenesis as primary pathophysiological events in a significant number of congenital hydrocephalus cases. The study was published on October 19, 2020 in the journal Nature Medicine.
Related Links:
Yale University School of Medicine
Latest Pathology News
- Collaboration Applies AI Pathology to Predict Response to Antibody-Drug Conjugates
- Biomarker Predicts Immunotherapy Response and Prognosis in Colorectal Cancer
- AI Improves Completeness of Complex Cancer Pathology Reports
- AI Tool Predicts Chemotherapy Response in Small Cell Lung Cancer
- Tumor-Specific Biomarker Predicts Neoadjuvant Immunotherapy Response in Gastric Cancer
- AI Tool Predicts Patient-Specific Chemotherapy Benefit in Breast Cancer
- AI-Based Pathology Model Guides Chemotherapy Decisions in Breast Cancer
- Biopsy-Based Gene Test Predicts Recurrence Risk in Lung Adenocarcinoma
- New Chromogenic Culture Media Enable Rapid Detection of Candida Infections
- AI-Powered Tool to Transform Dermatopathology Workflow
- AI Tool Predicts Chemotherapy Response from Biopsy Slides
- Sex Differences in Alzheimer’s Biomarkers Linked to Faster Cognitive Decline
- World’s First Optical Microneedle Device to Enable Blood-Sampling-Free Clinical Testing
- Novel mcPCR Technology to Transform Testing of Clinical Samples
- Pathogen-Agnostic Testing Reveals Hidden Respiratory Threats in Negative Samples
- Molecular Imaging to Reduce Need for Melanoma Biopsies
Channels
Clinical Chemistry
view channel
Blood Test Predicts Alzheimer Disease Risk Before Imaging Changes and Symptoms
Alzheimer's disease often advances silently for years, making timely risk stratification difficult in routine practice. Current approaches to detect pathology can involve lumbar puncture or positron emission... Read more
Study Finds ApoB Testing More Effective Than LDL for Guiding Lipid Therapy
Routine blood tests that measure low-density lipoprotein (LDL), commonly known as “bad” cholesterol, are widely used to guide lipid-lowering therapy, but they do not always provide a complete picture of... Read more
AI-Enabled POC Test Quantifies Multiple Cardiac Biomarkers
Cardiovascular diseases are a leading cause of death, responsible for nearly 20 million deaths each year. Timely triage of myocardial infarction and heart failure hinges on rapid cardiac biomarker measurement,... Read moreNext Generation Automated Analyzers Increase Throughput for Clinical Chemistry and Electrolyte Testing
Clinical laboratories continue to face staffing shortages, limited space, and growing test volumes that pressure chemistry and electrolyte workflows. Maintaining rapid turnaround times increasingly depends... Read moreHematology
view channel
Routine Blood Test Parameters Link Anemia to Cancer Risk and Mortality
Anemia detected in routine care can signal underlying pathology and is frequently encountered in adults. Because it is defined by hemoglobin levels below the normal range, it is often evaluated with red... Read more
Prognostic Tool Guides Personalized Treatment in Rare Blood Cancer
Chronic myelomonocytic leukemia (CMML) is a rare blood cancer in which acquired genetic mutations in bone marrow stem cells drive disease. Stem cell transplantation is the only curative option but carries... Read moreImmunology
view channel
Study Finds Influenza Often Undiagnosed in Winter Deaths
Seasonal influenza drives substantial excess mortality, yet its contribution is often obscured when infections go undiagnosed near the time of death. Many deaths occur outside hospitals or in older adults... Read moreCombined Screening Approach Identifies Early Leprosy Cases
Leprosy remains a significant public health concern, with more than 200,000 new cases reported globally each year and early disease often escaping routine laboratory detection. In its initial phase, bacterial... Read moreMicrobiology
view channelRapid Color Test Stratifies Virulent and Resistant Staph Strains
Staphylococcus aureus (golden staph) remains a leading cause of infection-related mortality worldwide, responsible for more than a million deaths each year. Rapidly distinguishing highly virulent or a... Read more
Syndromic Panel Enables Rapid Identification of Bloodstream Infections
Bloodstream infections require rapid identification of causative pathogens and resistance determinants to guide therapy, yet laboratories often face pressure to deliver clinically relevant results quickly... Read more
RNA-Based Workflow Identifies Active Skin Microbes for Dermatology Research
Human skin carries diverse microbial communities that influence barrier function and inflammation, yet identifying which organisms are metabolically active has been challenging. DNA-based surveys catalog... Read more
Cost-Effective Sampling and Sequencing Workflow Identifies ICU Infection Hotspots
Intensive care units face persistent threats from hospital-acquired infections, increasingly driven by drug-resistant bacteria. Rapidly pinpointing environmental reservoirs and transmission hotspots remains... Read morePathology
view channel
Biomarker Predicts Immunotherapy Response and Prognosis in Colorectal Cancer
Colorectal cancer is common and often lethal, and therapeutic decision-making is complicated by heterogeneous tumor microenvironments. Immunotherapy benefits only a small subset of patients, around 5%,... Read more
Collaboration Applies AI Pathology to Predict Response to Antibody-Drug Conjugates
Antibody-drug conjugates (ADC) are reshaping oncology, yet scalable biomarkers that reliably predict which patients will benefit remain limited as treatment regimens and combinations grow more complex.... Read moreTechnology
view channel
AI Tool Predicts Non-Response to Targeted Therapy in Colorectal Cancer
Advanced bowel cancer remains difficult to treat, and many patients receive targeted therapies that do not help them but still cause harm. Clinicians need reliable ways to identify likely responders before... Read more
Integrated System Streamlines Pre-Analytical Workflow for Molecular Testing
Pre-analytical variation remains a leading source of inconsistent molecular test results and added costs, particularly when laboratories rely on multiple instruments and protocols. Standardizing nucleic... Read moreIndustry
view channel
Partnership Expands Ultrasensitive WGS Assay for for Hematologic Malignancies and MRD Monitoring
Tempus AI and Predicta Biosciences announced the commercial expansion of a co-branded whole‑genome sequencing assay GenoPredicta, which is intended for comprehensive genomic characterization of hematologic... Read more







